Evaluation of lentiviral vector production shows scalability and reproducibility across multiple formats, suggesting improvements in therapeutic availability.
Increasing clinical demand for lentiviral vector–based therapies is driving the need for scalable and reproducible manufacturing workflows. This article presents an evaluation of lentiviral production across shake flask, 2 L, and 50 L formats, achieving infectious titers approaching 1 × 10⁸ TU/mL with comparable metabolic performance between formats. A 3 L implementation study further examines transferability of upstream parameters and identified operational variables influencing reproducibility at intermediate scale.
No takes yet. Share an insight, caveat, or question.
Zmuda et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: